Nonalcoholic Fatty Liver Disease (Nafld), More Than a Liver Disease

Parise, Edison Roberto

doi:10.1590/s0004-2803.201900000-45

Cited by 4 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The worldwide panel of liver pathologies also comprises chronic viral hepatitis, alcoholic liver disease, metabolic and cholestatic liver dysfunctions ( Asrani et al, 2019 ; WGO, 2020 ). Although NAFLD was identified more than 50 years ago ( Parise, 2019 ; Sanyal, 2019 ), the therapeutic options to treat or at least to control these diseases rely on long-term procedures and are still limited to weight loss and diet modification, stressing the critical need for innovative strategies based on fast and reliable preclinical tests.…”

Section: The Burden Of Hepatic Diseases Needs Translational Sciencementioning

confidence: 99%

Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases

Moraes

Montagne

2021

Front. Physiol.

View full text Add to dashboard Cite

Animal experimentation is limited by unethical procedures, time-consuming protocols, and high cost. Thus, the development of innovative approaches for disease treatment based on alternative models in a fast, safe, and economic manner is an important, yet challenging goal. In this paradigm, the fruit-fly Drosophila melanogaster has become a powerful model for biomedical research, considering its short life cycle and low-cost maintenance. In addition, biological processes are conserved and homologs of ∼75% of human disease-related genes are found in the fruit-fly. Therefore, this model has been used in innovative approaches to evaluate and validate the functional activities of candidate molecules identified via in vitro large-scale analyses, as putative agents to treat or reverse pathological conditions. In this context, Drosophila offers a powerful alternative to investigate the molecular aspects of liver diseases, since no effective therapies are available for those pathologies. Non-alcoholic fatty liver disease is the most common form of chronic hepatic dysfunctions, which may progress to the development of chronic hepatitis and ultimately to cirrhosis, thereby increasing the risk for hepatocellular carcinoma (HCC). This deleterious situation reinforces the use of the Drosophila model to accelerate functional research aimed at deciphering the mechanisms that sustain the disease. In this short review, we illustrate the relevance of using the fruit-fly to address aspects of liver pathologies to contribute to the biomedical area.

show abstract

Section: The Burden Of Hepatic Diseases Needs Translational Sciencementioning

confidence: 99%

Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases

Moraes

Montagne

2021

Front. Physiol.

View full text Add to dashboard Cite

show abstract

“…FLD is commonly associated with T2DM and other metabolic disorders, and there are about a third to two thirds of T2DM patients have FLD [ 3 ]. Numerous studies have proven that FLD, including steatohepatitis, is an independent risk factor for T2DM, and it is considered a modifiable factor in T2DM risk management and prevention [ 8 – 11 ]. In addition, studies suggested a bidirectional causal association between FLD and T2DM, and this is reflect in the fact that not only do FLD increase the incidence of T2DM, but T2DM can also promote the progression of FLD.…”

Section: Introductionmentioning

confidence: 99%

Population attributable fractions of fatty liver disease for type 2 diabetes Mellitus

Xu,

Wu,

Deng

et al. 2023

BMC Endocr Disord

View full text Add to dashboard Cite

Purpose To determine the population attributable fraction (PAF) of fatty liver disease (FLD) for type 2 diabetes mellitus (T2DM) and compare it to the PAFs of other metabolic abnormalities. Methods We conducted a 10-year retrospective cohort study of 33,346 individuals in Karamay Central Hospital of Xinjiang. Individuals were followed up for T2DM occurrence based on FBS. The PAFs of FLD were calculated generally and respectively in different sex and age groups. A comparison of the PAF of FLD and that of other metabolic abnormalities, as well as the PAFs of FLD in different groups classified based on age and sex, was performed using Cox regression. Results During an average follow-up period of 3.71 years, 1486 T2DM were diagnosed. The incidence density of T2DM was 1.2/100 person-years, and cumulative incidence rate was 4456.31/100,000 person-years. Partial PAF (PAFp) of FLD in the entire population was 23.11%. In the male population, PAFp was higher at 30–40 years old. In the female population, it was higher when age ≥ 60 years old. In multivariable Cox regression model, FLD, male sex, age ≥ 45 years old, overweight, hypertriglyceridaemia, and systolic hypertension were independent risk factors for T2DM, with corresponding PAFp of 25.00%, 24.99%, 36.47%, 24.96%, 5.71%, and 6.76%, respectively. Age ≥ 45 years old showed the highest PAFp and adjusted hazard ratio, followed by FLD. Conclusions FLD contributes more to T2DM incidence than other metabolic disorders. Particular attention should be given to male populations of 30–40 and female populations above 60 for FLD prevention and treatment.

show abstract

Cardiovascular comorbidity in non-alcoholic fatty liver disease

Тимакова¹,

Скирденко²,

Ливзан³

et al. 2020

jour

View full text Add to dashboard Cite

Актуальной проблемой современной медицины является поиск связей между неалкогольной жировой болезнью печени и сердечно-сосудистыми заболеваниями. Реальная клиническая практика нуждается в углублении знаний о взаимном влиянии этих патологий и разработке алгоритмов сопровождения таких коморбидных пациентов.В обзоре актуальной литературы показаны данные об увеличении кардиоваскулярных рисков и ускорении прогрессирования патологии печени при сочетании неалкогольной жировой болезни печени и сердечно-сосудистых заболеваний. В статье описаны звенья патогенеза неалкогольной жировой болезни печени, оказывающие влияние на развитие сердечно-сосудистых заболеваний (инсулинорезистентность, гипоадипонектинемия, гиперлептинемия, нарушения липидного обмена, активация воспаления и др.). Продемонстрирована роль воспаления, гормональных изменений и влияние кишечной микробиоты на течение обоих заболеваний. В обзоре представлены данные о влиянии общих факторов риска (нарушение липидного обмена, нарушение углеводного обмена, ожирение и др.) на течение обеих патологий. Приведены данные литературы о связи неалкогольной жировой болезни печени с развитием артериальной гипертензии (прежде всего за счет увеличения жесткости сосудистой стенки), ишемической болезнью Тимакова Арина Юрьевна, студент 4 курса лечебного факультета Скирденко Юлия Петровна, ассистент кафедры факультетской терапии, профессиональных болезней, кандидат медицинский наук Ливзан Мария Анатольевна, ректор, заведующий кафедрой факультетской терапии, профессиональных болезней, профессор, д. м. н. Кролевец Татьяна Сергеевна, ассистент кафедры факультетской терапии, профессиональных болезней, кандидат медицинский наук Николаев Николай Анатольевич, профессор кафедры факультетской терапии, профессиональных болезней, доцент, д. м. н. Нелидова Анастасия Владимировна, доцент кафедры пропедевтики внутренних болезней, доцент, кандидат медицинский наук Arina Yu. Timakova, medical faculty, student

show abstract

Nonalcoholic Fatty Liver Disease (Nafld), More Than a Liver Disease

Cited by 4 publications

References 39 publications

Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases

Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases

Population attributable fractions of fatty liver disease for type 2 diabetes Mellitus

Cardiovascular comorbidity in non-alcoholic fatty liver disease

Contact Info

Product

Resources

About